Filgrastim - Biologic Drug Details

Summary for filgrastim

Tradenames:	1
High Confidence Patents:	5
Applicants:	4
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for filgrastim

Recent Clinical Trials for filgrastim

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Takeda	PHASE2
City of Hope Medical Center	PHASE1
Diakonos Oncology Corporation	PHASE1

See all filgrastim clinical trials

Pharmacology for filgrastim

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for filgrastim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for filgrastim Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2006-03-03	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2009-03-06	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2015-06-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2015-06-02	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2015-05-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for filgrastim Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2036-12-20	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2035-10-19	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2035-11-20	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2035-04-01	Patent claims search
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353		2034-03-14	Patent claims search

International Patents for filgrastim

Country	Patent Number	Estimated Expiration
Finland	871700
Denmark	175551
Japan	2718426
Singapore	48964
Hong Kong	1029600

Supplementary Protection Certificates for filgrastim

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C300637	Netherlands		PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725
2014/006	Ireland		PRODUCT NAME: LONQUEX-LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725
SPC/GB14/009	United Kingdom		PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729
6/2003	Austria		PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822
300637	Netherlands		PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130729

Market Dynamics and Financial Trajectory for Filgrastim

Last updated: February 27, 2026

What is the Current Market Size and Growth Rate?

Filgrastim, a granulocyte colony-stimulating factor (G-CSF), primarily treats neutropenia caused by chemotherapy, bone marrow transplantation, and other hematological disorders. As of 2022, the global filgrastim market was valued at approximately USD 3.2 billion. It is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2028, reaching an estimated USD 4.6 billion by 2028. The growth is driven by expanding indications, increased cancer prevalence, and regulatory approvals for biosimilars.

What Are Key Market Drivers?

• Rising Cancer Incidence: Worldwide, cancer cases are increasing by around 4% annually. The demand for supportive care drugs like filgrastim matches this trend.
• Adoption of Biosimilars: The expiration of patents for Neupogen (original filgrastim) in several markets has led to biosimilar competition, reducing costs and expanding access.
• Expanded Indications: Use in stem cell mobilization, severe chronic neutropenia, and graft-versus-host disease (GVHD) broadens the market.

How Do Regulatory and Patent Landscapes Affect Market Dynamics?

• Patent expirations: The US patent for Neupogen expired in 2015; in Europe, it expired in 2018. Biosimilars from companies like Sandoz and Amgen entered the market subsequently.
• Regulatory approvals: Agencies such as the FDA and EMA have approved several biosimilars, with over 10 biosimilar filgrastims approved globally as of 2023.
• Pricing and reimbursement policies: Countries with strict price controls, like the UK and Germany, see biosimilar adoption faster, influencing overall market dynamics.

What Are the Main Competitive Players?

Company	Product Name	Market Share (2022)	Key Markets
Amgen	Neupogen, Nivestym	45%	North America, Europe
Sandoz	Zarzio, Grastofil	25%	Europe, North America, Asia-Pacific
Mylan (now part of Viatris)	Filgrastim Mylan	10%	Asia-Pacific, emerging markets
Others	Various biosimilars	20%	Global

Amgen remains the market leader due to early US market entry and established manufacturing. Biosimilar competition has gained significant footholds especially in Europe and Asia-Pacific.

How Does Pricing Influence Market Trajectory?

• Biosimilar introduction has reduced prices by up to 50% in some markets.
• Price erosions influence revenue streams for originators but expand patient access.
• Reimbursement policies favor biosimilar uptake, contributing to overall sales volume growth.

What Are Future Revenue Projections?

By 2028, revenues are forecasted to surpass USD 4.5 billion annually, assuming continued biosimilar adoption and expansion into new indications such as additional hematological disorders.

What Are Key Risks Affecting Financial Trajectory?

• Regulatory changes: Stringent approval processes may delay biosimilar entry.
• Patent litigation: Original manufacturers may defend patents, delaying biosimilar market entry.
• Manufacturing costs: High costs associated with biologics and biosimilars could impact profit margins, particularly in lower-income regions.

How Will Market and Clinical Trends Shape the Future?

• Introduction of more biosimilars may drive prices downward.
• Novel formulations or delivery mechanisms could update the product profile.
• Growing acceptance of biosimilars in developing countries will increase total market size.

Key Takeaways

• The global filgrastim market stood at USD 3.2 billion in 2022 and is expected to grow at 6.2% CAGR through 2028.
• Biosimilars dominate the market due to patent expirations, leading to price reductions and increased access.
• Major players include Amgen, Sandoz, and Viatris, with market shares of approximately 45%, 25%, and 10%, respectively.
• Adoption is driven by rising cancer prevalence and expanding indications; regulatory policies and pricing trends significantly influence growth.
• Long-term growth faces risks from regulatory hurdles and patent disputes but will be sustained by biosimilar proliferation and emerging markets.

FAQs

1. How does patent expiration affect filgrastim revenue?
Patent expiration allows biosimilar manufacturers to enter markets, reducing prices and increasing competition. This decreases revenue for original product producers but broadens access.

2. What is the primary driver behind the increasing demand for filgrastim?
The rising incidence of chemotherapy-induced neutropenia in cancer patients globally fuels demand.

3. How do biosimilars impact global market growth?
Biosimilars lower treatment costs, enabling wider adoption, especially in developing economies, with the potential to substantially increase total market size.

4. What markets are most competitive for filgrastim?
North America and Europe are mature markets with significant biosimilar penetration. Asia-Pacific trends are rapidly shifting with increased biosimilar approvals.

5. What technological advancements could affect the future of filgrastim?
Development of alternative formulations, improved delivery mechanisms, and novel biosimilars may influence market dynamics and revenues.

References

1. MarketsandMarkets. (2022). Filgrastim market analysis.
2. IQVIA. (2023). Global biosimilar report.
3. FDA. (2023). Biosimilar approval guidelines.
4. European Medicines Agency. (2023). Biosimilar approvals overview.
5. EvaluatePharma. (2023). Oncology supportive care market forecast.